title: [Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas].
abstract: Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response. To reduce the side effects caused by systemic administration of propranolol, timolol maleate treatment has been increasingly used as an alternative to systemic β-blockers and watchful waiting for many IH patients in recent years. However, the appropriate indications, drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects still remains controversial. To standardize the use of topical timolol in treating IH, avoid overtreatment or under-treatment, as well as minimize complications, a Chinese expert consensus on the use of topical timolol treatment of IH has been approved and written by a multidisciplinary experts group based on an up-to-date literature review and repeated discussion, which can be used to reduce inappropriate variations in clinical practice and to promote the delivery of high quality, evidence-based health care for IH patients.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011, China. E-mail:davidzhengjw@sjtu.edu.cn.
authors.forename: Jia-Wei
authors.initials: JW
authors.lastname: Zheng
authors.forename: Xu-Kai
authors.initials: XK
authors.lastname: Wang
authors.forename: Cheng-Hong
authors.initials: CH
authors.lastname: Jiang
authors.forename: Zhong-Ping
authors.initials: ZP
authors.lastname: Qin
authors.forename: Xin-Dong
authors.initials: XD
authors.lastname: Fan
authors.forename: Yao-Wu
authors.initials: YW
authors.lastname: Yang
authors.forename: Ran
authors.initials: R
authors.lastname: Huo
authors.forename: Shao-Hua
authors.initials: SH
authors.lastname: Liu
authors.forename: Ji-Hong
authors.initials: JH
authors.lastname: Zhao
authors.forename: Xiao-Yong
authors.initials: XY
authors.lastname: Wang
authors.forename: De-Kai
authors.initials: DK
authors.lastname: Zhou
authors.forename: Shao-Rong
authors.initials: SR
authors.lastname: Lei
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D044466:Asian People; D032921:Consensus; D005104:Expert Testimony; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D011433:Propranolol; D012878:Skin Neoplasms / Q000188:drug therapy*; D013999:Timolol / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D013999:Timolol; D011433:Propranolol